Circio Holding ASA (CRNA) - Net Assets
Based on the latest financial reports, Circio Holding ASA (CRNA) has net assets worth Nkr518.86 Million NOK (≈ $54.60 Million USD) as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Nkr545.56 Million ≈ $57.41 Million USD) and total liabilities (Nkr26.70 Million ≈ $2.81 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Circio Holding ASA PP&E and investment ratio to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Nkr518.86 Million |
| % of Total Assets | 95.11% |
| Annual Growth Rate | N/A |
| 5-Year Change | -102.99% |
| 10-Year Change | N/A |
| Growth Volatility | 1837.45 |
Circio Holding ASA - Net Assets Trend (2020–2025)
This chart illustrates how Circio Holding ASA's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see Circio Holding ASA (CRNA) market capitalisation.
Annual Net Assets for Circio Holding ASA (2020–2025)
The table below shows the annual net assets of Circio Holding ASA from 2020 to 2025. Also explore CRNA year-over-year net asset growth to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | Nkr-12.49 Million ≈ $-1.31 Million |
+0.14% |
| 2024-12-31 | Nkr-12.51 Million ≈ $-1.32 Million |
+87.31% |
| 2023-12-31 | Nkr-98.54 Million ≈ $-10.37 Million |
-3940.26% |
| 2022-12-31 | Nkr2.57 Million ≈ $270.02K |
-99.39% |
| 2021-12-31 | Nkr417.73 Million ≈ $43.96 Million |
+12.11% |
| 2020-12-31 | Nkr372.59 Million ≈ $39.21 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Circio Holding ASA's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 62703300000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | Nkr85.93 Million | % |
| Total Equity | Nkr-12.49 Million | 100.00% |
Circio Holding ASA Competitors by Market Cap
The table below lists competitors of Circio Holding ASA ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
SolGold PLC
TO:SOLG
|
$293.08 Million |
|
Relais Group Oyj
HE:RELAIS
|
$293.12 Million |
|
Hypothekarbank Lenzburg AG
SW:HBLN
|
$293.12 Million |
|
Korea No. 9 Special Purpose Acquisition Co. Ltd.
KQ:368770
|
$293.14 Million |
|
LEXINFINTECH ADR/2 CL.A
F:1LFA
|
$292.98 Million |
|
Strike Energy Ltd
AU:STX
|
$292.88 Million |
|
Aten International Co Ltd
TW:6277
|
$292.84 Million |
|
Samji Electronics Co. Ltd
KQ:037460
|
$292.83 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Circio Holding ASA's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from -12,509,000 to -12,492,000, a change of 17,000.
- Net loss of 45,907,000 reduced equity.
- Other factors increased equity by 45,924,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Nkr-45.91 Million | -367.49% |
| Other Changes | Nkr45.92 Million | +367.63% |
| Total Change | Nkr- | % |
Book Value vs Market Value Analysis
This analysis compares Circio Holding ASA's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2020-12-31 | Nkr92.56 | Nkr10.16 | x |
| 2021-12-31 | Nkr66.55 | Nkr10.16 | x |
| 2022-12-31 | Nkr0.38 | Nkr10.16 | x |
| 2023-12-31 | Nkr-12.66 | Nkr10.16 | x |
| 2024-12-31 | Nkr-0.17 | Nkr10.16 | x |
| 2025-12-31 | Nkr-0.08 | Nkr10.16 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Circio Holding ASA utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-2820.50%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2020 | -29.02% | -17327.88% | 0.00x | 1.40x | Nkr-145.38 Million |
| 2021 | -23.45% | 0.00% | 0.00x | 1.35x | Nkr-139.74 Million |
| 2022 | -16870.54% | -4328.11% | 0.10x | 39.13x | Nkr-433.15 Million |
| 2023 | 0.00% | -91821.95% | 0.00x | 0.00x | Nkr-103.09 Million |
| 2024 | 0.00% | 0.00% | 0.00x | 0.00x | Nkr58.77 Million |
| 2025 | 0.00% | 0.00% | 0.00x | 0.00x | Nkr-44.66 Million |
Industry Comparison
This section compares Circio Holding ASA's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $169,916,208
- Average return on equity (ROE) among peers: -71.48%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Circio Holding ASA (CRNA) | Nkr518.86 Million | -29.02% | 0.05x | $293.06 Million |
| Arcticzymes Technologies ASA (AZT) | $244.84 Million | 18.94% | 0.16x | $109.63 Million |
| Bergenbio ASA (BGBIO) | $337.28 Million | -56.85% | 0.12x | $7.75 Million |
| Exact Therapeutics AS (EXTX) | $45.10 Million | -107.17% | 0.36x | $4.69 Million |
| Lytix Biopharma AS (LYTIX) | $189.62 Million | -25.34% | 0.07x | $68.46 Million |
| Nykode Therapeutics ASA (NYKD) | $194.06 Million | -4.85% | 0.37x | $160.89 Million |
| Oncoinvent ASA (ONCIN) | $127.48 Million | -149.36% | 0.37x | $39.49 Million |
| PCI Biotech Holding ASA (PCIB) | $189.24 Million | -38.17% | 0.11x | $274.95K |
| SoftOx Solutions AS (SOFTX) | $22.95 Million | -47.11% | 0.48x | $34.09 Million |
| Thor Medical ASA (TRMED) | $178.67 Million | -233.44% | 0.76x | $202.29 Million |
About Circio Holding ASA
Circio Holding ASA, a biotechnology company, develops novel circular RNA expression technology for gene and cell therapy. The company is developing TG01, a cancer vaccine targeting driver mutations, which is in three clinical trials for multiple myeloma, and pancreatic and lung cancer; and circVec circRNA vector platform, a modular genetic cassette for biogenesis of multifunctional circRNAs in hu… Read more